Natera (NTRA) Stock Forecast & Price Target

$102.67

+0.52 (+0.51%)

(As of 07/26/2024 ET)

Natera - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy
Based on 16 Analyst Ratings

Based on 16 Wall Street analysts who have issued ratings for Natera in the last 12 months, the stock has a consensus rating of "Buy." Out of the 16 analysts, 16 have given a buy rating for NTRA.

Consensus Price Target

$101.19
-1.44% Downside

High Forecast	$142.00
Average Forecast	$101.19
Low Forecast	$68.00

According to the 16 analysts' twelve-month price targets for Natera, the average price target is $101.19. The highest price target for NTRA is $142.00, while the lowest price target for NTRA is $68.00. The average price target represents a forecasted downside of -1.44% from the current price of $102.67.

Type	Current Forecast 7/28/23 to 7/27/24	1 Month Ago 6/28/23 to 6/27/24	3 Months Ago 4/29/23 to 4/28/24	1 Year Ago 7/28/22 to 7/28/23
Consensus Rating	Buy	Buy	Buy	Buy
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	16 Buy rating(s)	16 Buy rating(s)	14 Buy rating(s)	6 Buy rating(s)
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$101.19	$101.19	$86.40	$72.40
Forecasted Upside	-1.44% Downside	24.67% Upside	26.67% Upside	44.78% Upside

Get Natera Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for NTRA and its competitors with MarketBeat's FREE daily newsletter.

Ad Weiss Ratings

Nvidia’s Quiet $1 Trillion Pivot

Nvidia recently added $277 billion in market cap … IN ONE DAY.

Find out details on these three critical Nvidia partners immediately.

NTRA Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

NTRA Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Natera Stock vs. The Competition

Type	Natera	Medical Companies	S&P 500
Consensus Rating Score	3.00	2.72	2.50
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	-1.44% Downside	3,123.46% Upside	9.10% Upside
News Sentiment Rating	Neutral News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Action	Rating	Price Target	Upside/Downside on Report Date
6/3/2024	Jefferies Financial Group 2 of 5 stars	Initiated Coverage	Buy	$142.00	+33.30%
5/14/2024	Piper Sandler 2 of 5 stars	Boost Target	Overweight ➝ Overweight	$110.00 ➝ $120.00	+16.13%
5/13/2024	BTIG Research 2 of 5 stars	Boost Target	Buy ➝ Buy	$100.00 ➝ $125.00	+21.11%
5/10/2024	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$100.00 ➝ $130.00	+23.66%
5/10/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$123.00 ➝ $137.00	+30.23%
5/10/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Outperform ➝ Outperform	$99.00 ➝ $117.00	+22.45%
Get the Latest News and Ratings for NTRA and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Natera and its competitors with MarketBeat's FREE daily newsletter.
4/15/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$90.00 ➝ $100.00	+7.93%
4/8/2024	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$117.00	+21.23%
4/5/2024	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$120.00	+29.93%
2/20/2024	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Outperform	$68.00 ➝ $85.00	+21.41%
1/30/2024	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$78.00	+17.49%
12/14/2023	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$70.00	+16.51%
12/13/2023	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$70.00	+19.62%
11/10/2023	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Overweight ➝ Overweight	$70.00 ➝ $68.00	+45.49%
11/9/2023	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy ➝ Buy	$76.00 ➝ $70.00	+54.12%
8/4/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$70.00	+37.34%
8/5/2022	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target		$80.00 ➝ $100.00	+94.97%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 06:49 AM ET.

NTRA Forecast - Frequently Asked Questions

What is Natera's forecast for 2024?: According to the research reports of 16 Wall Street equities research analysts, the average twelve-month stock price forecast for Natera is $101.19, with a high forecast of $142.00 and a low forecast of $68.00.
Should I buy or sell Natera stock right now?: 16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Natera in the last year. There are currently 16 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" NTRA shares.
Does Natera's stock price have much upside?: According to analysts, Natera's stock has a predicted upside of 24.67% based on their 12-month stock forecasts.
What analysts cover Natera?: Natera has been rated by research analysts at BTIG Research, Canaccord Genuity Group, Jefferies Financial Group, Piper Sandler, Robert W. Baird, and TD Cowen in the past 90 days.
Do Wall Street analysts like Natera more than its competitors?: Analysts like Natera more than other "medical" companies. The consensus rating for Natera is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how NTRA compares to other companies.